logo
Alaskan Woman's Death From Gonorrhea Sparks Fears of a New Strain

Alaskan Woman's Death From Gonorrhea Sparks Fears of a New Strain

Gizmodo03-07-2025
A well-known sexually transmitted infection might be causing more trouble than usual in Alaska. Local health officials this week have reported the death of a woman in her 50s from a rare complication of gonorrhea that's becoming increasingly more common in the state.
On Monday, the Alaska Department of Health detailed the tragic death in its latest epidemiology bulletin. The woman died from an untreated gonorrhea infection that had spread widely throughout her body. Health officials are worried that novel strains of the bacteria may be behind a spike of similar cases reported in the area over the past three years.
Gonorrhea is caused by the bacteria Neisseria gonorrhoeae, and it's one of the most commonly reported STIs worldwide. In 2023, there were over 600,000 documented cases of gonorrhea in the U.S. alone. Common symptoms include puke-colored genital discharge and bloody urination, as well as swollen testicles in men and bleeding between periods for women. One reason why gonorrhea is dangerous, however, is that it often doesn't cause symptoms at all. And when it goes unnoticed and untreated, it can potentially trigger infertility and raise the risk of catching other STIs. If it's passed down from mother to child in the womb, the infection can also cause severe complications like blindness in the newborn.
The Rise of Super Gonorrhea
Seldomly, the bacteria migrate away from where they normally infect us (the genitals and sometimes the throat) to other parts of the body. This complication is called a disseminated gonococcal infection, or DGI. DGIs can cause varying health problems, depending on where the bacteria end up, such as arthritis or skin lesions. On very rare occasions, the infection can turn lethal if it reaches vital areas like the heart or bloodstream.
In this particular case, the woman visited a local emergency room in Anchorage earlier this spring with symptoms of respiratory distress. She was diagnosed with septic shock and heart failure caused by endocarditis (an inflammation of the inner lining of our heart's valves and chambers). Tests confirmed the widespread presence of gonorrhea bacteria in her body and bloodstream. Soon after, she succumbed to her infection.
While DGI is rare, and deaths from it even rarer, something strange appears to be happening in Alaska as of late. Since 2023, there's been a marked increase in reported DGI cases. In 2024, there were 24 documented cases—three times higher than the tally reported in 2023 (eight cases) and ten times higher than 2022 (two cases). So far in 2025, there have been eight reported cases of DGI, still well above the typical average in Alaska and the U.S. as a whole.
In many of these cases, including the latest one, people experienced no or few symptoms of their gonorrhea prior to their DGI. They also often had no clear risk factors for an STI and sometimes even tested negative on standard urine and genital swab tests for gonorrhea. Though officials haven't identified a specific link or chain of transmission between these cases, they suspect that emerging strains of gonorrhea could be causing the local rise in DGI. These strains might be more likely to cause DGI in general, or they might be less likely to cause initial symptoms, allowing infections to go untreated at a higher rate than typical.
Though there are still many questions to be answered, health officials are warning residents to be especially proactive about their sexual health.
'People in the Anchorage area with a new sexual partner, more than one sexual partner, or a partner with multiple partners might be at risk of acquiring a strain of N. gonorrhoeae thought to carry a higher risk of causing DGI,' the health department stated in its bulletin. Officials are recommending that people with these risk factors get regularly tested for gonorrhea every three to six months.
Super Gonorrhea May Have Met Its Nemesis
This isn't the only recent new trick that gonorrhea has gotten up its sleeve. Other strains of the bacteria have increasingly evolved resistance to the last remaining frontline drugs available against it. These cases of super gonorrhea, while still rare, are spreading as well. Just last month, researchers reported the first such case discovered in Canada.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Respiree Secures Second FDA 510(k) Clearance, Expands Cardio-Respiratory Wearable to Home Use via 1Bio™ Connected Care Platform
Respiree Secures Second FDA 510(k) Clearance, Expands Cardio-Respiratory Wearable to Home Use via 1Bio™ Connected Care Platform

Yahoo

time6 minutes ago

  • Yahoo

Respiree Secures Second FDA 510(k) Clearance, Expands Cardio-Respiratory Wearable to Home Use via 1Bio™ Connected Care Platform

HOUSTON and SINGAPORE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, today announced it has received its second U.S. Food and Drug Administration (FDA) 510(k) clearance. The clearance expands the use of its RS001 cardio-respiratory wearable to home environments and includes approval for its connected care platform marketed as 1Bio™. Illustrative Image of Respiree's RS001 Wearable With its Connected Care 1Bio™ Platform The RS001 is a chest-worn device that directly measures respiration and offers passive cardio-respiratory monitoring. Originally cleared for in-patient clinical use, the RS001's use in home settings marks a significant step toward more accessible and preventive healthcare. The device connects to a cellular hub, which enables data to be visualized in real time via the connected care 1Bio™ dashboard. 'Respiration is the most predictive vital sign for clinical deterioration, yet it remains underutilized – particularly outside hospital settings,' said Dr. Gurpreet Singh, CEO and Founder of Respiree. 'This FDA 510(k) extension allows healthcare systems to passively and accurately monitor leading indicators in the home, enabling earlier interventions and reducing the overall burden on healthcare infrastructure.' The announcement follows Respiree's recent US$11.6 million Series A financing round, led by We Venture Capital and ClavystBio, which will accelerate development toward potential regulatory approvals and global market expansion. Respiree also announced plans to pursue additional FDA clearances for its proprietary AI software, aiming to integrate artificial intelligence models into the 1Bio™ platform for both inpatient and home-based care. 'These are exciting times for us,' added Dr. Singh. 'Our first 510(k) was for the wearable; this second one is for the platform. We are now focused on bringing our flagship AI models into the fold as a Software as a Medical Device (SaMD).' About Respiree Respiree™ is an AI/ML health tech company building state-of-the-art clinically-validated artificial intelligence (AI) for managing disease progression across healthcare's care continuum. The 1Bio™ platform by Respiree™ uses data from the EHR and its proprietary US-patented and FDA-cleared sensors to longitudinal measure and track disease progression. Respiree™ is now available in U.S., Australia and Asia-Pacific (APAC). Respiree™ is CE marked, has received regulatory clearances in Australia from the Therapeutics Goods Administration and has received the 510k clearance from the United States Food and Drug Administration (FDA). ( Media Enquiries Evangeline FuAdministrative ManagerRespiree Pte LtdEmail: evangeline@ A photo accompanying this announcement is available at in to access your portfolio

‘Childhood verbal abuse can have similar mental health impact as physical abuse'
‘Childhood verbal abuse can have similar mental health impact as physical abuse'

Yahoo

time6 minutes ago

  • Yahoo

‘Childhood verbal abuse can have similar mental health impact as physical abuse'

Verbal abuse of children could be as damaging to their mental health in adulthood as physical abuse, according to researchers. A study of more than 20,000 adults in England and Wales found that people exposed to verbal abuse in childhood were likely to feel disconnected, pessimistic, and emotionally unwell in later life. Adults who were physically abused as children had a 52% higher chance of experiencing low mental wellbeing, and this stood at around 64% for those who had been subjected to solely verbal abuse. While verbal abuse did show as having a marginally higher impact in this study, the researchers said the difference was not statistically significant and that further studies would be needed perhaps with a larger sample size to confirm the validity of the difference. Being exposed to both types of abuse compounded the risk even further, at 115% higher, the study led by Liverpool John Moores University found. Lead author, Professor Mark Bellis, who is director of research and innovation at the university, said: 'Our research shows that verbal abuse in childhood may inflict mental health scars as deep and enduring as those caused by physical abuse. Important progress has been made in reducing physical abuse, but verbal abuse is often overlooked.' The study, published in the BMJ Open, also suggested the prevalence of verbal abuse has risen in recent decades 'eroding the long-term mental health benefits we should see from reducing physical abuse'. The authors worked alongside Bangor University and Public Health Wales to pool data from seven relevant studies, involving 20,687 adults from England and Wales and looking at birth cohorts from the 1950s onwards. They found that the prevalence of child physical abuse halved from around 20% among those born between 1950 and 1979 to 10% among those born in 2000 or later. But when it came to verbal abuse, the prevalence rose from 12% among those born before 1950 to around 20% among those born in 2000 or later. The researchers said an estimated one in six children endure physical abuse, primarily from family members and caregivers, but one in three are subjected to verbal abuse. Jessica Bondy, founder of Words Matter, an organisation focused on ending childhood verbal abuse by adults said: 'This study confirms what survivors and professionals have long known: words can wound deeply and have a lasting impact on a child's mental health and development. We all get overloaded sometimes, but too many adults are turning to harsh words without realising the lasting damage they cause to children. 'Any gains made in reducing physical abuse risk being undone by rising rates of verbal abuse. We must act now to confront the lasting harm caused by cruel, critical or controlling language. We need to build children up – not knock them down. The mental health of the next generation and our shared future depend on it.'

Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Yahoo

time6 minutes ago

  • Yahoo

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Piper Sandler senior research analyst Yasmin Rahini on August 7, 2025 at 11:00amEST. The event will be webcast live and the registration link can be found here. About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit and follow us on Facebook, Instagram, LinkedIn and Twitter/X. CONTACT: Investor Contact: Praxis Precision Medicines investors@ 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@ 617-430-7576Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store